Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020437 (
hypercalcemia
)
10,293
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In order to investigate the frequency of fasting hypergastrinaemia in primary hyperparathyroidism (A) and in chronic
hypercalcaemia
(B), in 40 and 16 patients respectively gastrin, parathyroid hormone (PTH) and serum calcium levels were measured and compared with those of a control group (40 subjects) with similar distribution of sex and age. Moreover, possible linear relationships between these parameters were investigated. Notwithstanding significant differences in calcium and PTH levels between the three groups (A: high PTH, high Ca++; B: low PTH, high Ca++; C: normal PTH and Ca++ levels), no significant difference in gastrin levels were found. However, in the first group, a marked increase of gastrin was observed in one patient, very probably affected by a gastrin-secreting
tumor
(positive secretin test). While no linear relationship between PTH and gastrin values was present in all the three groups, a significant correlation between serum calcium and fasting gastrin was detectable in the group A, ruling-out the above mentioned patient. Present data suggest that PTH does not modify gastrin levels and that chronic moderate
hypercalcaemia
does not raise serum fasting gastrin, at least in clinical conditions. Moreover, the frequency of hypergastrinaemia in hyperparathyroidism is very low and it seems to be present only in patients with gastrin-secreting tumors.
...
PMID:Fasting serum gastrin in primary hyperparathyroidism and in chronic hypercalcemia. 54 29
Genitourinary tumors account for half of all documented cases of pseudohyperparathyroidism. The treatment of
hypercalcemia
is directed toward immediate correction of the electrolyte imbalance and long-term control. These goals are accomplished with volume repletion, calcium normalization and removal of the
tumor
. Effective therapy includes saline infusion and furosemide. Additional control is obtained with phosphates and/or indomethachin. In refractory cases actinomycin-D or mithramycin is helpful. The first reported case of urethral cancer and second reported case of testicular seminoma producing this syndrome are added to the literature.
...
PMID:Genitourinary malignancy and pseudohyperparathyroidism. 56 30
A case of
hypercalcemia
associated with documented squamous cell carcinoma of the renal pelvis without bony metastasis is reported. Pseudohyperparathyroidism was suspected strongly because of the radioimmunoassay values of parathormone. This was confirmed by the prompt decrease of serum calcium after removal of the
neoplasm
. The radiologic findings were non-specific.
...
PMID:Squamous cell carcinoma of the renal pelvis presenting with hypercalcemia. 62 97
An unusual finding of systemic calcinosis in a patient with a nonparathyroid malignant neoplasm stimulated us to do a sclinicopathologic review of similar cases at our institution in the past seven years. Of 3,268 autopsies performed from 1968 to 1975, a total of 17 cases of calcinosis were found, 11 with solid tumors and 6 with hematopoietic neoplasms. Calcinosis was most prominent in the lung, kidney, heart, and stomach and was rarely discovered prior to death. Eighty-two percent of the patients had
hypercalcemia
and 53% had associated bony metastatic disease. Corticosteroid or phosphate treatment for the
hypercalcemia
may have contributed to the tissue deposition of calcium. Significant hepatic, renal, metabolic, and pulmonary dysfunctions were also associated with this disorder. Thirty-six percent of the patients had
hypercalcemia
without skeletal involvement;
tumor
-produced parathormone-like substances may be responsible for these calcium abnormalities. Calcinosis was a significant complication of
neoplastic disease
in these patients and contributed to morbidity and mortality.
...
PMID:Calcinosis in nonparathyroid malignant disease: an unusual case report and clinicopathologic review of 17 cases. 62 63
A
tumor
in the anterior mediastinum was found in an adult male German Shorthaired Pointer. The dog presented with
hypercalcemia
that varied with the removal and recurrence of the
tumor
. The
neoplasm
was characterized by an encapsulated multilobed grey-white soft mass with stroma, and the recurrent
tumor
infiltrated veins and the heart. The
tumor
consisted of groups of clear cells with well outlined cytoplasmic boundaries separated by thin vascular stroma. These cells had few organelles, scattered clumps of glycogen, clear cytosol and prominent infolding and interdigitating plasma membranes and desmosomes. The clinical, light and electron microscopic features were consistent with a functional
neoplasm
of parathyroid tissue origin.
...
PMID:Mediastinal parathyroid adenocarcinoma in a dog. 62 69
A patient with adrenocortical carcinoma had three major endocrine abnormalities attributable directly to the
tumor
: hypercortisolism (Cushing's syndrome), hyperestrogenism (feminization), and
hypercalcemia
(pseudohyperparathyroidism). There were higher levels of immunoreactive parathyroid hormone in venous effluent from the
tumor
or its abdominal metastases compared to that found in the veins draining the parathyroid glands. This, together with the presence of normal parathyroid glands on autopsy, established the diagnosis of pseudohyperparathyroidism as the cause of
hypercalcemia
in this patient.
...
PMID:Feminizing adrenocortical carcinoma with Cushing's syndrome and pseudohyperparathyroidism. 62 58
Squamous cell carcinoma of the skin is an extremely rare cause of
hypercalcemia
associated with malignant neoplasms. The case of a patient with extensive squamous cell carcinoma of both buttocks and thighs, with severe
hypercalcemia
is reported. The data presented indicate secretion of a humoral factor by the
tumor
, producing
hypercalcemia
.
...
PMID:Hypercalcemia in squamous cell carcinoma of the skin. 64 17
Results of previous studies have shown that the VX2 carcinoma in rabbits synthesizes large amounts of prostaglandin E2 (PGE2). PGE2 secreted by the
tumor
is rapidly metabolized and can be measured in plasma as the metabolite 13,14-dihydro-15-keto-PGE2 (PGE2-M). We have previously proposed that the
hypercalcemia
that occurs in rabbits bearing the VX2 carcinoma is due to excessive secretion of PGE2 by the
tumor
and its subsequent action on the skeleton as a bone resorption-stimulating factor. In the course of these studies, we noted that the plasma of rabbits bearing the VS2 carcinoma became blue about 1 wk after
tumor
implantation. The intensity of the color increased markedly thereafter. We therefore measured ceruloplasmin in plasma by both chemical and immunological assay methods. Plasma ceruloplasmin and PGE2-M rose in parallel (within 7-10 days) and preceded by 7-10 days the development of
hypercalcemia
. 2 wk after
tumor
implantation, plasma PGE2-M and ceruloplasmin had risen about 20- and 6-fold, respectively, while the rise in plasma calcium was just beginning. Indomethacin, an inhibitor of prostaglandin synthesis, given from the time of
tumor
implantation prevented completely the
hypercalcemia
and largely inhibited the rise in ceruloplasmin. When given after hyperprostaglandinemia had developed, indomethacin produced a fall in both PGE2-M and ceruloplasmin. A rise in plasma haptoglobin concentrations similar to that seen for ceruloplasmin was also observed. No changes in plasma albumin concentrations occurred. We conclude that the acute phase reactants ceruloplasmin and haptoglobin rise rapidly in the plasma of rabbits bearing the VX2 carcinoma, and that this increase is related to arachidonic acid metabolism in these animals. It is possible that arachidonic acid metabolites also play a role in the elevations of these two plasma proteins observed in certain patients with malignant tumors.
...
PMID:Acute phase reactants ceruloplasmin and haptoglobin and their relationship to plasma prostaglandins in rabbits bearing the VS2 carcinoma. 65 Jan 52
Various hormones have been implicated in the genesis of
hypercalcemia
in patients with malignancy. Ectopic secretion of PTH by
tumor
has been documented in only a few patients; rather, elevated levels of circulating iPTH have been presumed to reflect
tumor
production of hormone in most patients. Small fragments of PTH, as well as polypeptides larger than native PTH, have been described; their biological roles are unclear. The pattern of immunoreactivity, however, has been used to differentiate patients with ectopic hyperparathyroidism from patients with concomitant primary hyperparathyroidism. Vitamin D-like sterols produced by breast cancer seldom reach plasma levels necessary for physiological effects. Members of the prostaglandin family have been proposed to induce
hypercalcemia
through osteoclast activation or alteration of the immune system and also to affect the frequency of bone metastases. At present, no direct evidence is available to prove a direct role for these effects and prostaglandins are most useful as possible indicators of disease activity.
...
PMID:Mechanisms of hypercalcemia in malignancy. 65 92
A patient with poorly differentiated monocytic malignancy had extensive lytic lesions of bone and
hypercalcemia
. The patient's bone margins showed little evidence of osteoclast activity. Serum parathormone concentrations were slightly increased relative to the degree of
hypercalcemia
, consistent with impaired renal function. Serum concentrations of the relevant prostaglandins were normal. Supernatant medium from cultured
tumor
cells caused prominent bone resorption in vitro. The studies on this patient provide evidence that malignant cells of the monocyte-macrophage line are capable of direct bone resorption.
...
PMID:Production of bone resorbing activity in poorly differentiated monocytic malignancy. 65 6
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>